Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CNN reporting today that the Ferguson, Missouri PD has received 3 donated wearable video cameras from a private company that have been put into use.
Form 8-K filed after the close:
http://biz.yahoo.com/e/140829/dgly8-k.html
Double your pleasure with $IMSC. US government fiscal year is ending on September 30, 2014. The new fiscal year is beginning on October 1, 2014. Opportunity knocks twice in very short order for the Quantum Sniffer-B220.
So true. Just look how long homeland security stock IMSC had to wait for TSA approval from the US government. Take a look at a 5 year chart and see where they came from and where they are now. Material contracts are anticipated by the market for IMSC shortly so watch where they will go. Hope the same is true for LLLI.
While Implant Sciences' revolutionary unique TSA-approved technology is non-radioactive IMSC the stock is!
While Implant Sciences' revolutionary unique TSA-approved technology is non-radioactive $IMSC the stock is!
On Twitter this evening Pennybuster and Superman are Re-Tweeting or Favoriting favorable Tweets about IMSC. Together the 2 have 38.000 followers on Twitter.
$IMSC spotlighted by Boston area media:
www.lowellsun.com/latestnews/ci_26425570/implant-sciences-product-earns-key-certification
http://blogs.lowellsun.com/itsyourbusiness/2014/08/28/implant-sciences-shares-shake-out/#sthash.bdp7Hnvt
Boston area media spotlights IMSC:
www.lowellsun.com/latestnews/ci_26425570/implant-sciences-product-earns-key-certification
http://blogs.lowellsun.com/itsyourbusiness/2014/08/28/implant-sciences-shares-shake-out/#sthash.bdp7Hnvt
Grilled Buffalo for dinner tonight!
$IMSC Reached a New 52 Week High at $1.39
Alert Triggered for Implant Sciences Corp.
IMSC rose 15.83% to a new 52 week high of $1.39. During the last 52 weeks, IMSC's price has ranged from $0.72 on February 14, 2014 to today's high of $1.39.
Additionally, over the last 12 months, IMSC has increased 28.70% while its peers in the Electronic Equipment & Instruments industry increased 20.27%.
Please note you will receive only one "New 52 Week High" alert per day for Implant Sciences Corp.
$IMSC Reached a New 52 Week High at $1.39
Alert Triggered for Implant Sciences Corp.
IMSC rose 15.83% to a new 52 week high of $1.39. During the last 52 weeks, IMSC's price has ranged from $0.72 on February 14, 2014 to today's high of $1.39.
Additionally, over the last 12 months, IMSC has increased 28.70% while its peers in the Electronic Equipment & Instruments industry increased 20.27%.
Please note you will receive only one "New 52 Week High" alert per day for Implant Sciences Corp.
$IMSC Price Alert on TSA product approval - Implant Sciences Corp. (IMSC) Price Changed +10.00% from Wednesday's Close
Alert Triggered for Implant Sciences Corp
IMSC increased +10.00% today and is currently trading at $1.32. This performance was better than its Electronic Equipment & Instruments industry peers as they fell 0.62%.
Please note you will receive only one "Price Changes 10% Since the Prior Day's Close" alert per day for Implant Sciences Corp.
$IMSC Price Alert on TSA product approval - Implant Sciences Corp. (IMSC) Price Changed +10.00% from Wednesday's Close
Alert Triggered for Implant Sciences Corp
IMSC increased +10.00% today and is currently trading at $1.32. This performance was better than its Electronic Equipment & Instruments industry peers as they fell 0.62%.
Please note you will receive only one "Price Changes 10% Since the Prior Day's Close" alert per day for Implant Sciences Corp.
$IMSC big upmove as it receives TSA approval for passenger screening explosive trace detectors. #AmericanMade #Non-Radioactive
$IMSC big upmove as it receives TSA approval for passenger screening explosive trace detectors. #AmericanMade #Non-Radioactive
Here we go!
Here we go!
I see a potential class action suit coming for this buyunder.
Security stocks strong today $TASR $DGLY $LLLI. $IMSC next IMO on anticipated TSA deal.
Security stocks strong today $TASR $DGLY $LLLI. $IMSC next IMO on anticipated TSA deal.
$CONX - Corgenix Medical: Broomfield's Corgenix ramps up efforts on Ebola diagnostic test
By Alicia Wallace
Daily Camera Business Writer
Posted: 08/11/2014 07:42:54 PM MDT
As the current Ebola outbreak grows more dire in West Africa, a greater urgency has been placed on efforts underway locally to develop a commercial test to rapidly detect the onset of the deadly virus.
However, it's too soon to tell how much the work being done by Corgenix Medical Corp. could be accelerated, officials for the Broomfield-based diagnostics products maker said Monday.
In late June, Corgenix Medical Corp. was awarded a $2.9 million grant from the National Institutes of Health to further develop a prototype diagnostic test for the Ebola virus. The project's timeline is three years.
"There's a lot of urgency, a lot of interest in it," said Douglass Simpson, chief executive officer of Corgenix. "We're assembling our team, we're growing our team."
The deaths attributed to the Ebola outbreak in West Africa climbed to 1,013 on Monday, according to the World Health Organization.
Corgenix has commenced work under the grant, but it is premature to say whether the company would be able to accelerate that work and shave a couple months or a year off that three-year timetable, Simpson said.
"We'll try to accelerate this if we can," he said. "It takes a bit of time."
Corgenix, founded in 1990, develops a variety of diagnostic products that range from tests to determine aspirin's effectiveness in individual humans to assays that can rapidly detect viral hemorrhagic fevers such as Lassa.
The work on a Lassa diagnostic test — which resulted in Corgenix's ReLASV Antigen Rapid Test gaining a CE Mark, allowing for sale in the European Union — has made for an easier roadmap for the Ebola test, Simpson said.
"There are different antibodies, and it's detecting a different virus, but we're building on the knowledge we established under Lassa," he said. " ... I see no indication that it's not going to be successful. We're using the same model for Lassa products, and they're very effective."
The Ebola test resulted from a 2010 to 2012 research program conducted in partnership with the Viral Hemorrhagic Fever Consortium and funded with nearly $600,000 from the NIH.
Corgenix officials have said the Ebola assay identified potential indications of the deadly virus in 15 minutes after an initial screening and confirmed the diagnosis in a little more than an hour. Other testing methods can take a few hours.
The rapid test for Ebola has not been cleared or approved by any worldwide agency.
The latest $2.9 million grant is designed to take the test to a point where it could be commercialized, Simpson said.
The initial work on the tests will take place in Broomfield and in Viral Hemorrhagic Fever Consortium partner labs in places such as Galveston, Texas. The tests locally do not involve any live samples of the virus
The latter end of the work would involve additional research and testing in the areas where Ebola is endemic, he said.
Earlier this year, Corgenix shipped out hundreds of its prototype Ebola rapid tests as part of a "first line of defense" attempt to detect the virus in a matter of minutes.
Those prototype test supplies have since been exhausted and are no longer in use in the "hot zone" areas.
"Because of the severity of the outbreak, they shifted from screening," Simpson said. "Now anyone who shows symptoms (is brought in for medical care)."
No Corgenix officials are operating out of West Africa, although some other researchers within the Viral Hemorrhagic Fever Consortium remain in the area, he said.
"The people over there right now are MDs and they're just trying to help in the overall epidemic control; the research is really postponed," Simpson said. "We've got to take care of the people first. What we expect is once they get it cleaned up, it'll get back to business as usual."
Contact Camera Business Writer Alicia Wallace at 303-473-1332 or wallacea@dailycamera.com. Follow her at twitter.com/dc_alicia.
http://www.dailycamera.com/boulder-business/ci_26318701/broomfields-corgenix-ramps-up-efforts-ebola-diagnostic-test
$CONX - Corgenix Medical: Broomfield's Corgenix ramps up efforts on Ebola diagnostic test
By Alicia Wallace
Daily Camera Business Writer
Posted: 08/11/2014 07:42:54 PM MDT
As the current Ebola outbreak grows more dire in West Africa, a greater urgency has been placed on efforts underway locally to develop a commercial test to rapidly detect the onset of the deadly virus.
However, it's too soon to tell how much the work being done by Corgenix Medical Corp. could be accelerated, officials for the Broomfield-based diagnostics products maker said Monday.
In late June, Corgenix Medical Corp. was awarded a $2.9 million grant from the National Institutes of Health to further develop a prototype diagnostic test for the Ebola virus. The project's timeline is three years.
"There's a lot of urgency, a lot of interest in it," said Douglass Simpson, chief executive officer of Corgenix. "We're assembling our team, we're growing our team."
The deaths attributed to the Ebola outbreak in West Africa climbed to 1,013 on Monday, according to the World Health Organization.
Corgenix has commenced work under the grant, but it is premature to say whether the company would be able to accelerate that work and shave a couple months or a year off that three-year timetable, Simpson said.
"We'll try to accelerate this if we can," he said. "It takes a bit of time."
Corgenix, founded in 1990, develops a variety of diagnostic products that range from tests to determine aspirin's effectiveness in individual humans to assays that can rapidly detect viral hemorrhagic fevers such as Lassa.
The work on a Lassa diagnostic test — which resulted in Corgenix's ReLASV Antigen Rapid Test gaining a CE Mark, allowing for sale in the European Union — has made for an easier roadmap for the Ebola test, Simpson said.
"There are different antibodies, and it's detecting a different virus, but we're building on the knowledge we established under Lassa," he said. " ... I see no indication that it's not going to be successful. We're using the same model for Lassa products, and they're very effective."
The Ebola test resulted from a 2010 to 2012 research program conducted in partnership with the Viral Hemorrhagic Fever Consortium and funded with nearly $600,000 from the NIH.
Corgenix officials have said the Ebola assay identified potential indications of the deadly virus in 15 minutes after an initial screening and confirmed the diagnosis in a little more than an hour. Other testing methods can take a few hours.
The rapid test for Ebola has not been cleared or approved by any worldwide agency.
The latest $2.9 million grant is designed to take the test to a point where it could be commercialized, Simpson said.
The initial work on the tests will take place in Broomfield and in Viral Hemorrhagic Fever Consortium partner labs in places such as Galveston, Texas. The tests locally do not involve any live samples of the virus
The latter end of the work would involve additional research and testing in the areas where Ebola is endemic, he said.
Earlier this year, Corgenix shipped out hundreds of its prototype Ebola rapid tests as part of a "first line of defense" attempt to detect the virus in a matter of minutes.
Those prototype test supplies have since been exhausted and are no longer in use in the "hot zone" areas.
"Because of the severity of the outbreak, they shifted from screening," Simpson said. "Now anyone who shows symptoms (is brought in for medical care)."
No Corgenix officials are operating out of West Africa, although some other researchers within the Viral Hemorrhagic Fever Consortium remain in the area, he said.
"The people over there right now are MDs and they're just trying to help in the overall epidemic control; the research is really postponed," Simpson said. "We've got to take care of the people first. What we expect is once they get it cleaned up, it'll get back to business as usual."
Contact Camera Business Writer Alicia Wallace at 303-473-1332 or wallacea@dailycamera.com. Follow her at twitter.com/dc_alicia.
http://www.dailycamera.com/boulder-business/ci_26318701/broomfields-corgenix-ramps-up-efforts-ebola-diagnostic-test
$IMSC - Implant Sciences at Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
8:00 AM ET, 08/11/2014 - Business Wire
NEW YORK--(BUSINESS WIRE)--Aug. 11, 2014-- Rodman & Renshaw Conferences, LLC, today announced that – former United States Secretary of State and retired four star general – Colin L. Powell will present the keynote address for the 2014 Rodman & Renshaw Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, at The Palace Hotel in New York. General Colin L. Powell’s address is scheduled for Tuesday, September 9, 2014 at 8:00am in the Villard Ballroom. The Conference will be held September 9 and 10, 2014 with more than 250 public & private companies from around the world expected to present to an audience of over 2,000 attendees. The two day event will feature tracks devoted to Biotechnology/Healthcare, Metals & Mining, Technology, Cleantech and Growth. The Conference will include corporate presentations and Q&A sessions, investor one-on-one meetings and daily networking opportunities. Institutional investors, venture capitalists, private equity firms, sophisticated private investors and industry executives are welcome to attend this conference. Register online at the Rodman & Renshaw Conference website at www.rodm.com or contact Lily Khaykina, Rodman & Renshaw’s Conference Manager, at (212) 356-0529 or via e-mail at LK@rodm.com
Presenting Companies
Healthcare/Life Sciences
Metals & Mining
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) Adriana Resources Inc. (TSX: ADI.V)
Active Biotech AB (NASDAQ OMX Stockholm: ACTI) Alexco Resource Corp. (NYSE-MKT: AXU)
Advaxis, Inc. (NASDAQ: ADXS) AuRico Gold Inc. (NYSE: AUQ)
Aeterna Zentaris Inc. (Nasdaq: AEZS) Avalon Rare Metals Inc. (NYSE; TSX: AVL)
Agenus Inc. (NASDAQ: AGEN) Avino Silver & Gold Mines Ltd. (TSX-V, NYSE: ASM)
Akers Biosciences, Inc. (AKER: NASDAQ) Azarga Uranium Corp. (TSX: AZZ)
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Balmoral Resources Ltd. (TSX: BAR)
Alliqua, Inc. (NASDAQ: ALQA) Caledonia Mining Corporation (Toronto: CAL.TO)
Amarantus BioScience Holdings, Inc. (OTC BB: AMBS) Coeur Mining, Inc. (NYSE: CDE)
Amarin Corporation plc (NASDAQ: AMRN) Comstock Mining Inc. (NYSE MKT: LODE)
AmpliPhi Biosciences Corporation (OTC BB: APHB) Endeavour Silver Corp. (NYSE: EXK)
Anavex Life Sciences Corp. (OTC BB: AVXL)
Energold Drilling Corp. (Toronto Venture StockExchange: EGD.V)
AntriaBio, Inc. (OTC BB: ANTB)
Applied DNA Sciences, Inc. (OTC BB: APDN) Energy Fuels Inc. (NYSE MKT: UUUU)
Apricus Biosciences, Inc. (NASDAQ: APRI) Excalibur Resources Ltd. (OTCQX: EXCFF)
ARCA biopharma, Inc. (Nasdaq: ABIO) Fission Uranium Corp. (TSX.V: FCU.V)
Arch Therapeutics, Inc. (OTC: ARTH) Focus Graphite Inc. (TSX.V: FMS)
Argos Therapeutics, Inc. (ARGS: NASDAQ) General Moly, Inc. (NYSE MKT and TSX: GMO)
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) Golden Minerals Company (NYSE MKT: AUMN)
Arno Therapeutics, Inc. (OTCQB: ARNI) Golden Queen Mining Co. Ltd. (TSX / OTCQX: GQM)
Atossa Genetics, Inc. (NASDAQ: ATOS) Golden Star Resources Ltd. (NYSE MKT: GSS)
Biocept, Inc. (NASDAQ: BIOC)
Great Panther Silver Limited (TSX andNYSE MKT: GPR.TO; GPL NYS)
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)
BioLife Solutions, Inc. (NASDAQ: BLFS) Hecla Mining Company (NYSE: HL)
BioLight – Israeli Life Sciences Investments Ltd.(TASE: BOLT)
MAG Silver Corp. (NYSE MKT: MVG)
Mines Management, Inc. (NYSE MKT: MGN)
BioLineRx Ltd. (NASDAQ: BLRX) NovaGold Resources Inc. (TSX, NYSE-MKT: NG)
Bionomics Limited (ASX: BNO.AX) Paramount Gold and Silver Corp. (NYSE MKT: PZG)
BioSpecifics Technologies Corp. (NASDAQ: BSTC) Pershing Gold Corporation (OTC BB: PGLC)
BioTime, Inc. (NYSE: BTX) PolyMet Mining Corp. (NYSE MKT: PLM)
Boston Therapeutics, Inc. (OTCQB: BTHE) Rare Element Resources Ltd. (NYSE MKT: REE)
Brabant Pharma Revett Mining Company, Inc. (NYSE MKT / TSX: RVM)
Brainstorm Cell Therapeutics Inc. (OTC BB: BCLI) Solitario Exploration & Royalty Corp. (NYSE MKT: XPL)
BSD Medical Corporation (NASDAQ: BSDM) Stria Capital Inc. (TSX.V: SRA)
Cambrex Corporation (CBM: NYSE) Ur-Energy Inc. (NYSE MKT: URG)
Can-Fite BioPharma, Ltd. (NYSE MKT: CANF) Uranerz Energy Corporation (NYSE MKT: URZ)
Capstone Therapeutics Corp. (OTCQB: CAPS) Uranium Energy Corp. (NYSE MKT: UEC) (
Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) Uranium Resources, Inc. (NASDAQ: URRE)
Ceapro Inc. (TSX: CZO.V) Victory Nickel Inc. (TSX: NI.TO)
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) Vista Gold Corp. (NYSE MKT & TSX: VGZ)
Cell Source Ltd. (OTC BB: CLCS) Wellgreen Platinum Ltd. (TSX: WG.V)
Cellceutix Corporation (OTC: CTIX)
Cellectar Biosciences, Inc. (OTCQX: CLRB)
Technology
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) 5BARz International, Inc. (OTCQB: BARZ)
Celsion Corporation (NASDAQ: CLSN) Arotech Corporation (NASDAQ: ARTX)
Cesca Therapeutics Inc. (NASDAQ: KOOL) Camtek Ltd. (NASDAQ: CAMT)
Champions Oncology, Inc. (OTC BB: CSBR) China XD Plastics Company Limited (NASDAQ: CXDC)
Chembio Diagnostics, Inc. (NASDAQ: CEMI) Cimatron Ltd. (NASDAQ CM: CIMT)
Cleveland BioLabs, Inc. (Nasdaq: CBLI) Crowdgather, Inc. (OTCQB: CRWG)
CoDa Therapeutics, Inc. Data I/O Corporation (NASDAQ: DAIO)
Columbia Laboratories, Inc. (Nasdaq: CBRX) Dot Hill Systems Corp. (NASDAQ: HILL)
ContraVir Pharmaceuticals, Inc. (OTC BB: CTRV) DragonWave Inc. (NASDAQ: DRWI)
Corbus Pharmaceuticals, Inc. Elbit Vision Systems Ltd. (OTC BB: EVSNF)
Cortex Pharmaceuticals, Inc. (Other OTC: CORX) Implant Sciences Corporation (OTC: IMSC)
Critical Outcome Technologies Inc. (TSX: COT.V) Information Services Group, Inc. (NASDAQ: III)
Curis, Inc. (NASDAQ: CRIS) Inventergy Inc. (NASDAQ: INVT)
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Local Corporation (NASDAQ: LOCM)
Cynapsus Therapeutics Inc. (TSX.V: CTH.V)
Magic Software Enterprises Ltd. (NASDAQ Global SelectMarket: MGIC)
Cytomedix, Inc. (OTC BB: CMXI)
CytoSorbents Corporation (OTCBB: CTSO) NetDimensions (Holdings) Limited (OTCQX: NETDY)
CytRx Corporation (NASDAQ: CYTR) Novatel Wireless, Inc. (NASDAQ: NVTL)
DARA BioSciences, Inc. (NASDAQ: DARA) PCM, Inc. (NASDAQ: PCMI)
DelMar Pharmaceuticals, Inc. (OTC BB: DMPI) Pharma-Bio Serv, Inc. (OTCBB: PBSV)
Dendreon Corporation (NASDAQ: DNDN) Pointer Telocation Ltd. (NASDAQ: PNTR)
DiaMedica Inc. (TSX-V: DMA.V) RealNetworks, Inc. (NASDAQ: RNWK)
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) Rightscorp, Inc. (OTCQB: RIHT)
DURECT Corporation (NASDAQ: DRRX) Sebring Software, Inc. (OTC: SMXI)
EDAP TMS S.A. (NASDAQ: EDAP) Single Touch Systems, Inc. (OTC BB: SITO)
Elite Pharmaceuticals, Inc. (OTC BB: ELTP) Smith Micro Software, Inc. (NASDAQ: SMSI)
Elk OrthoBiologics Limited Soul and Vibe Interactive Inc. (OTCQB: SOUL)
Emisphere Technologies, Inc. (OTC BB: EMIS) SuperCom Ltd. (NASDAQ: SPCB)
Epizyme, Inc. (NASDAQ: EPZM) Surna Inc. (OTCQB: SRNA)
Fate Therapeutics, Inc. (NASDAQ: FATE) USA Technologies, Inc. (NASDAQ: USAT)
Galena Biopharma, Inc. (Nasdaq: GALE) UTStarcom Holdings Corp. (NASDAQ: UTSI)
GenSpera, Inc. (OTCQB: GNSZ) Viggle Inc. (NASDAQ: VGGL)
GenVec, Inc. (NASDAQ: GNVC) Viscount Systems Inc. (OTCQB: VSYS)
GeoVax Labs, Inc. (OTCQB: GOVX) Vuzix Corporation (OTCQB: VUZI)
Guided Therapeutics, Inc. (OTCQB: GTHP)
Heat Biologics, Inc. (Nasdaq: HTBX)
Cleantech
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI) Axion International Holdings, Inc. (OTCQB: AXIH)
Hemispherx Biopharma, Inc. (NYSE MKT: HEB) BioLargo, Inc. (OTCBB: BLGO)
Immune Pharmaceuticals, Inc. (OTC BB: IMNP) China Recycling Energy Corporation (NASDAQ: CREG)
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) Deinove S.A. (Paris: ALDEI.PA)
Insmed Incorporated (NASDAQ: INSM) Gulf Resources, Inc. (NASDAQ: GURE)
IntelGenx Technologies Corp. (Toronto and NYSE: IGXT) Magnolia Solar Corporation (OTC BB: MGLT)
International Stem Cell Corporation (OTC BB: ISCO) U.S. Geothermal, Inc. (NYSE MKT: HTM)
InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) UQM Technologies, Inc. (NYSE: UQM)
Kamada Ltd. (Nasdaq: KMDA)
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX)
Growth
La Jolla Pharmaceutical Company (NASDAQ: LJPC) Asia Pacific Wire & Cable Corporation Limited (NASDAQ:
LabStyle Innovations Corp. (OTC BB: DRIO) APWC)
Lion Biotechnologies, Inc. (LBIO: OTC BB) Calpian, Inc. (OTC BB: CLPI)
Lixte Biotechnology Holdings, Inc. (OTC BB: LIXT) China Green Agriculture, Inc. (NYSE: CGA)
MabVax Therapeutics Inc. (OTCQB: TELK) Highpower International, Inc. (NASDAQ: HPJ)
Marina Biotech, Inc. (OTC BB: MRNA) HPEV, Inc. (OTCBB: WARM)
Mast Therapeutics, Inc. (NYSE MKT: MSTX) Lifetime Brands, Inc. (NASDAQ: LCUT)
Matinas BioPharma, Inc. (OTCBB: MTNB) Manitex International, Inc. (NASDAQ: MNTX)
MaxCyte, Inc. Orient Paper, Inc. (NYSE: ONP)
Mayne Pharma Group Limited (ASX: MYX.AX) Reed’s, Inc. (NYSE MKT: REED)
MDxHealth, Inc. (EURONEXT: MDXH) Sysorex Global Holdings Corp. (NASDAQ: SYRX)
MELA Sciences, Inc. (NASDAQ: MELA) Top Image Systems Ltd. (NASDAQ: TISA)
Metastat, Inc. (OTCQB: MTST) Xueda Education Group (NYSE: XUE)
MYOS Corporation (OTC BB: MYOS)
NanoViricides, Inc. (NYSE.MKT: NNVC)
NeoStem, Inc. (Nasdaq: NBS)
NephroGenex, Inc. (NASDAQ: NRX)
Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT)
Neuralstem, Inc. (NYSE Amex: CUR)
NeuroMetrix, Inc. (NASDAQ: NURO)
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)
NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY)
Novan Therapeutics
Novogen Limited (NASDAQ: NVGN)
Nuvo Research Inc. (TSX: NRI.TO)
Ocera Therapeutics, Inc. (NASDAQ: OCRX)
OncoSec Medical Incorporated (OTC BB: ONCS)
Oncothyreon Inc. (Nasdaq: ONTY)
Opexa Therapeutics, Inc. (Nasdaq: OPXA)
Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP)
OSE Pharma SA
OvaScience, Inc. (NASDAQ: OVAS)
OXiGENE, Inc. (NASDAQ: OXGN)
PharmAthene, Inc. (NYSE MKT: PIP)
Pluristem Therapeutics Inc. (NASDAQ: PSTI)
PositiveID Corporation (OTC Markets: PSID)
Pressure BioSciences, Inc. (OTCQB: PBIO)
Prosensa Holding N.V. (NASDAQ: RNA)
Protalex, Inc. (OTC BB: PRTX)
Protalix BioTherapeutics, Inc. (NYSE MKT: PLX)
Provista Diagnostics, Inc.
PURE Bioscience, Inc. (OTC BB: PURE)
RedHill Biopharma Ltd. (NASDAQ: RDHL)
RepliCel Life Sciences Inc. (TSXV: RP)
RestorGenex Corporation (OTC BB: RESX)
Resverlogix Corp. (TSX: RVX.TO)
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN)
Rosetta Genomics Inc. (NASDAQ: ROSG)
Ruthigen, Inc. (NASDAQ: RTGN)
RXi Pharmaceuticals Corporation (NASDAQ: RXII)
Soligenix, Inc. (OTC BB: SNGX)
Sorrento Therapeutics, Inc. (NASDAQ: SRNE)
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
SQI Diagnostics Inc. (TSX.V: SQD.V)
Stellar Biotechnologies, Inc. (OTC QB: SBOTF)
StemCells, Inc. (NASDAQ: STEM)
Stemline Therapeutics, Inc. (Nasdaq: STML)
Stevia First Corp. (OTC BB: STVF)
Synthetic Biologics, Inc. (NYSE MKT: SYN)
Taxus Cardium Pharmaceuticals Group Inc. (OTC: CRXM)
TG Therapeutics, Inc. (NASDAQ: TGTX)
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
Titan Pharmaceuticals, Inc. (OTC BB: TTNP)
Tolero Pharmaceuticals, Inc.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP
Transgene S.A. (NYSE EURONEXT: TNG)
Transgenomic, Inc. (NASDAQ: TBIO)
Transition Therapeutics Inc. (Nasdaq: TTHI)
Trillium Therapeutics Inc. (OTCQX: SCTPF)
United Therapeutics Corporation (NASDAQ: UTHR)
Venaxis, Inc. (NASDAQ: APPY)
Vical Incorporated (NASDAQ: VICAL)
WaferGen Bio-systems, Inc. (OTC: WGBS)
CONFERENCE SPONSORS
Marquee Sponsor
H.C. WAINWRIGHT & CO, LLC
Gold Sponsors
Corporate Stock Transfer, Inc., Marcum LLP, William O’Neil + Company
Silver Sponsors
Bloomberg Brief, Castle Brands (NYSE MKT: ROX), Chord Advisors, Equities.com, IRTH Communications, MarketNexus Media, SEC Compliance, Sichenzia Ross Friedman Ference LLP, StockVest Quarterly, theIRapp®, Uber
Source: Rodman & Renshaw Conferences, LLC
Rodman & Renshaw Conferences, LLCLily Khaykina, 1-212-356-0529Conference ManagerLK@rodm.com
$IMSC - Implant Sciences at Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
8:00 AM ET, 08/11/2014 - Business Wire
NEW YORK--(BUSINESS WIRE)--Aug. 11, 2014-- Rodman & Renshaw Conferences, LLC, today announced that – former United States Secretary of State and retired four star general – Colin L. Powell will present the keynote address for the 2014 Rodman & Renshaw Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, at The Palace Hotel in New York. General Colin L. Powell’s address is scheduled for Tuesday, September 9, 2014 at 8:00am in the Villard Ballroom. The Conference will be held September 9 and 10, 2014 with more than 250 public & private companies from around the world expected to present to an audience of over 2,000 attendees. The two day event will feature tracks devoted to Biotechnology/Healthcare, Metals & Mining, Technology, Cleantech and Growth. The Conference will include corporate presentations and Q&A sessions, investor one-on-one meetings and daily networking opportunities. Institutional investors, venture capitalists, private equity firms, sophisticated private investors and industry executives are welcome to attend this conference. Register online at the Rodman & Renshaw Conference website at www.rodm.com or contact Lily Khaykina, Rodman & Renshaw’s Conference Manager, at (212) 356-0529 or via e-mail at LK@rodm.com
Presenting Companies
Healthcare/Life Sciences
Metals & Mining
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) Adriana Resources Inc. (TSX: ADI.V)
Active Biotech AB (NASDAQ OMX Stockholm: ACTI) Alexco Resource Corp. (NYSE-MKT: AXU)
Advaxis, Inc. (NASDAQ: ADXS) AuRico Gold Inc. (NYSE: AUQ)
Aeterna Zentaris Inc. (Nasdaq: AEZS) Avalon Rare Metals Inc. (NYSE; TSX: AVL)
Agenus Inc. (NASDAQ: AGEN) Avino Silver & Gold Mines Ltd. (TSX-V, NYSE: ASM)
Akers Biosciences, Inc. (AKER: NASDAQ) Azarga Uranium Corp. (TSX: AZZ)
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Balmoral Resources Ltd. (TSX: BAR)
Alliqua, Inc. (NASDAQ: ALQA) Caledonia Mining Corporation (Toronto: CAL.TO)
Amarantus BioScience Holdings, Inc. (OTC BB: AMBS) Coeur Mining, Inc. (NYSE: CDE)
Amarin Corporation plc (NASDAQ: AMRN) Comstock Mining Inc. (NYSE MKT: LODE)
AmpliPhi Biosciences Corporation (OTC BB: APHB) Endeavour Silver Corp. (NYSE: EXK)
Anavex Life Sciences Corp. (OTC BB: AVXL)
Energold Drilling Corp. (Toronto Venture StockExchange: EGD.V)
AntriaBio, Inc. (OTC BB: ANTB)
Applied DNA Sciences, Inc. (OTC BB: APDN) Energy Fuels Inc. (NYSE MKT: UUUU)
Apricus Biosciences, Inc. (NASDAQ: APRI) Excalibur Resources Ltd. (OTCQX: EXCFF)
ARCA biopharma, Inc. (Nasdaq: ABIO) Fission Uranium Corp. (TSX.V: FCU.V)
Arch Therapeutics, Inc. (OTC: ARTH) Focus Graphite Inc. (TSX.V: FMS)
Argos Therapeutics, Inc. (ARGS: NASDAQ) General Moly, Inc. (NYSE MKT and TSX: GMO)
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) Golden Minerals Company (NYSE MKT: AUMN)
Arno Therapeutics, Inc. (OTCQB: ARNI) Golden Queen Mining Co. Ltd. (TSX / OTCQX: GQM)
Atossa Genetics, Inc. (NASDAQ: ATOS) Golden Star Resources Ltd. (NYSE MKT: GSS)
Biocept, Inc. (NASDAQ: BIOC)
Great Panther Silver Limited (TSX andNYSE MKT: GPR.TO; GPL NYS)
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)
BioLife Solutions, Inc. (NASDAQ: BLFS) Hecla Mining Company (NYSE: HL)
BioLight – Israeli Life Sciences Investments Ltd.(TASE: BOLT)
MAG Silver Corp. (NYSE MKT: MVG)
Mines Management, Inc. (NYSE MKT: MGN)
BioLineRx Ltd. (NASDAQ: BLRX) NovaGold Resources Inc. (TSX, NYSE-MKT: NG)
Bionomics Limited (ASX: BNO.AX) Paramount Gold and Silver Corp. (NYSE MKT: PZG)
BioSpecifics Technologies Corp. (NASDAQ: BSTC) Pershing Gold Corporation (OTC BB: PGLC)
BioTime, Inc. (NYSE: BTX) PolyMet Mining Corp. (NYSE MKT: PLM)
Boston Therapeutics, Inc. (OTCQB: BTHE) Rare Element Resources Ltd. (NYSE MKT: REE)
Brabant Pharma Revett Mining Company, Inc. (NYSE MKT / TSX: RVM)
Brainstorm Cell Therapeutics Inc. (OTC BB: BCLI) Solitario Exploration & Royalty Corp. (NYSE MKT: XPL)
BSD Medical Corporation (NASDAQ: BSDM) Stria Capital Inc. (TSX.V: SRA)
Cambrex Corporation (CBM: NYSE) Ur-Energy Inc. (NYSE MKT: URG)
Can-Fite BioPharma, Ltd. (NYSE MKT: CANF) Uranerz Energy Corporation (NYSE MKT: URZ)
Capstone Therapeutics Corp. (OTCQB: CAPS) Uranium Energy Corp. (NYSE MKT: UEC) (
Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) Uranium Resources, Inc. (NASDAQ: URRE)
Ceapro Inc. (TSX: CZO.V) Victory Nickel Inc. (TSX: NI.TO)
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) Vista Gold Corp. (NYSE MKT & TSX: VGZ)
Cell Source Ltd. (OTC BB: CLCS) Wellgreen Platinum Ltd. (TSX: WG.V)
Cellceutix Corporation (OTC: CTIX)
Cellectar Biosciences, Inc. (OTCQX: CLRB)
Technology
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) 5BARz International, Inc. (OTCQB: BARZ)
Celsion Corporation (NASDAQ: CLSN) Arotech Corporation (NASDAQ: ARTX)
Cesca Therapeutics Inc. (NASDAQ: KOOL) Camtek Ltd. (NASDAQ: CAMT)
Champions Oncology, Inc. (OTC BB: CSBR) China XD Plastics Company Limited (NASDAQ: CXDC)
Chembio Diagnostics, Inc. (NASDAQ: CEMI) Cimatron Ltd. (NASDAQ CM: CIMT)
Cleveland BioLabs, Inc. (Nasdaq: CBLI) Crowdgather, Inc. (OTCQB: CRWG)
CoDa Therapeutics, Inc. Data I/O Corporation (NASDAQ: DAIO)
Columbia Laboratories, Inc. (Nasdaq: CBRX) Dot Hill Systems Corp. (NASDAQ: HILL)
ContraVir Pharmaceuticals, Inc. (OTC BB: CTRV) DragonWave Inc. (NASDAQ: DRWI)
Corbus Pharmaceuticals, Inc. Elbit Vision Systems Ltd. (OTC BB: EVSNF)
Cortex Pharmaceuticals, Inc. (Other OTC: CORX) Implant Sciences Corporation (OTC: IMSC)
Critical Outcome Technologies Inc. (TSX: COT.V) Information Services Group, Inc. (NASDAQ: III)
Curis, Inc. (NASDAQ: CRIS) Inventergy Inc. (NASDAQ: INVT)
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Local Corporation (NASDAQ: LOCM)
Cynapsus Therapeutics Inc. (TSX.V: CTH.V)
Magic Software Enterprises Ltd. (NASDAQ Global SelectMarket: MGIC)
Cytomedix, Inc. (OTC BB: CMXI)
CytoSorbents Corporation (OTCBB: CTSO) NetDimensions (Holdings) Limited (OTCQX: NETDY)
CytRx Corporation (NASDAQ: CYTR) Novatel Wireless, Inc. (NASDAQ: NVTL)
DARA BioSciences, Inc. (NASDAQ: DARA) PCM, Inc. (NASDAQ: PCMI)
DelMar Pharmaceuticals, Inc. (OTC BB: DMPI) Pharma-Bio Serv, Inc. (OTCBB: PBSV)
Dendreon Corporation (NASDAQ: DNDN) Pointer Telocation Ltd. (NASDAQ: PNTR)
DiaMedica Inc. (TSX-V: DMA.V) RealNetworks, Inc. (NASDAQ: RNWK)
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) Rightscorp, Inc. (OTCQB: RIHT)
DURECT Corporation (NASDAQ: DRRX) Sebring Software, Inc. (OTC: SMXI)
EDAP TMS S.A. (NASDAQ: EDAP) Single Touch Systems, Inc. (OTC BB: SITO)
Elite Pharmaceuticals, Inc. (OTC BB: ELTP) Smith Micro Software, Inc. (NASDAQ: SMSI)
Elk OrthoBiologics Limited Soul and Vibe Interactive Inc. (OTCQB: SOUL)
Emisphere Technologies, Inc. (OTC BB: EMIS) SuperCom Ltd. (NASDAQ: SPCB)
Epizyme, Inc. (NASDAQ: EPZM) Surna Inc. (OTCQB: SRNA)
Fate Therapeutics, Inc. (NASDAQ: FATE) USA Technologies, Inc. (NASDAQ: USAT)
Galena Biopharma, Inc. (Nasdaq: GALE) UTStarcom Holdings Corp. (NASDAQ: UTSI)
GenSpera, Inc. (OTCQB: GNSZ) Viggle Inc. (NASDAQ: VGGL)
GenVec, Inc. (NASDAQ: GNVC) Viscount Systems Inc. (OTCQB: VSYS)
GeoVax Labs, Inc. (OTCQB: GOVX) Vuzix Corporation (OTCQB: VUZI)
Guided Therapeutics, Inc. (OTCQB: GTHP)
Heat Biologics, Inc. (Nasdaq: HTBX)
Cleantech
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI) Axion International Holdings, Inc. (OTCQB: AXIH)
Hemispherx Biopharma, Inc. (NYSE MKT: HEB) BioLargo, Inc. (OTCBB: BLGO)
Immune Pharmaceuticals, Inc. (OTC BB: IMNP) China Recycling Energy Corporation (NASDAQ: CREG)
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) Deinove S.A. (Paris: ALDEI.PA)
Insmed Incorporated (NASDAQ: INSM) Gulf Resources, Inc. (NASDAQ: GURE)
IntelGenx Technologies Corp. (Toronto and NYSE: IGXT) Magnolia Solar Corporation (OTC BB: MGLT)
International Stem Cell Corporation (OTC BB: ISCO) U.S. Geothermal, Inc. (NYSE MKT: HTM)
InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) UQM Technologies, Inc. (NYSE: UQM)
Kamada Ltd. (Nasdaq: KMDA)
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX)
Growth
La Jolla Pharmaceutical Company (NASDAQ: LJPC) Asia Pacific Wire & Cable Corporation Limited (NASDAQ:
LabStyle Innovations Corp. (OTC BB: DRIO) APWC)
Lion Biotechnologies, Inc. (LBIO: OTC BB) Calpian, Inc. (OTC BB: CLPI)
Lixte Biotechnology Holdings, Inc. (OTC BB: LIXT) China Green Agriculture, Inc. (NYSE: CGA)
MabVax Therapeutics Inc. (OTCQB: TELK) Highpower International, Inc. (NASDAQ: HPJ)
Marina Biotech, Inc. (OTC BB: MRNA) HPEV, Inc. (OTCBB: WARM)
Mast Therapeutics, Inc. (NYSE MKT: MSTX) Lifetime Brands, Inc. (NASDAQ: LCUT)
Matinas BioPharma, Inc. (OTCBB: MTNB) Manitex International, Inc. (NASDAQ: MNTX)
MaxCyte, Inc. Orient Paper, Inc. (NYSE: ONP)
Mayne Pharma Group Limited (ASX: MYX.AX) Reed’s, Inc. (NYSE MKT: REED)
MDxHealth, Inc. (EURONEXT: MDXH) Sysorex Global Holdings Corp. (NASDAQ: SYRX)
MELA Sciences, Inc. (NASDAQ: MELA) Top Image Systems Ltd. (NASDAQ: TISA)
Metastat, Inc. (OTCQB: MTST) Xueda Education Group (NYSE: XUE)
MYOS Corporation (OTC BB: MYOS)
NanoViricides, Inc. (NYSE.MKT: NNVC)
NeoStem, Inc. (Nasdaq: NBS)
NephroGenex, Inc. (NASDAQ: NRX)
Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT)
Neuralstem, Inc. (NYSE Amex: CUR)
NeuroMetrix, Inc. (NASDAQ: NURO)
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)
NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY)
Novan Therapeutics
Novogen Limited (NASDAQ: NVGN)
Nuvo Research Inc. (TSX: NRI.TO)
Ocera Therapeutics, Inc. (NASDAQ: OCRX)
OncoSec Medical Incorporated (OTC BB: ONCS)
Oncothyreon Inc. (Nasdaq: ONTY)
Opexa Therapeutics, Inc. (Nasdaq: OPXA)
Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP)
OSE Pharma SA
OvaScience, Inc. (NASDAQ: OVAS)
OXiGENE, Inc. (NASDAQ: OXGN)
PharmAthene, Inc. (NYSE MKT: PIP)
Pluristem Therapeutics Inc. (NASDAQ: PSTI)
PositiveID Corporation (OTC Markets: PSID)
Pressure BioSciences, Inc. (OTCQB: PBIO)
Prosensa Holding N.V. (NASDAQ: RNA)
Protalex, Inc. (OTC BB: PRTX)
Protalix BioTherapeutics, Inc. (NYSE MKT: PLX)
Provista Diagnostics, Inc.
PURE Bioscience, Inc. (OTC BB: PURE)
RedHill Biopharma Ltd. (NASDAQ: RDHL)
RepliCel Life Sciences Inc. (TSXV: RP)
RestorGenex Corporation (OTC BB: RESX)
Resverlogix Corp. (TSX: RVX.TO)
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN)
Rosetta Genomics Inc. (NASDAQ: ROSG)
Ruthigen, Inc. (NASDAQ: RTGN)
RXi Pharmaceuticals Corporation (NASDAQ: RXII)
Soligenix, Inc. (OTC BB: SNGX)
Sorrento Therapeutics, Inc. (NASDAQ: SRNE)
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
SQI Diagnostics Inc. (TSX.V: SQD.V)
Stellar Biotechnologies, Inc. (OTC QB: SBOTF)
StemCells, Inc. (NASDAQ: STEM)
Stemline Therapeutics, Inc. (Nasdaq: STML)
Stevia First Corp. (OTC BB: STVF)
Synthetic Biologics, Inc. (NYSE MKT: SYN)
Taxus Cardium Pharmaceuticals Group Inc. (OTC: CRXM)
TG Therapeutics, Inc. (NASDAQ: TGTX)
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
Titan Pharmaceuticals, Inc. (OTC BB: TTNP)
Tolero Pharmaceuticals, Inc.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP
Transgene S.A. (NYSE EURONEXT: TNG)
Transgenomic, Inc. (NASDAQ: TBIO)
Transition Therapeutics Inc. (Nasdaq: TTHI)
Trillium Therapeutics Inc. (OTCQX: SCTPF)
United Therapeutics Corporation (NASDAQ: UTHR)
Venaxis, Inc. (NASDAQ: APPY)
Vical Incorporated (NASDAQ: VICAL)
WaferGen Bio-systems, Inc. (OTC: WGBS)
CONFERENCE SPONSORS
Marquee Sponsor
H.C. WAINWRIGHT & CO, LLC
Gold Sponsors
Corporate Stock Transfer, Inc., Marcum LLP, William O’Neil + Company
Silver Sponsors
Bloomberg Brief, Castle Brands (NYSE MKT: ROX), Chord Advisors, Equities.com, IRTH Communications, MarketNexus Media, SEC Compliance, Sichenzia Ross Friedman Ference LLP, StockVest Quarterly, theIRapp®, Uber
Source: Rodman & Renshaw Conferences, LLC
Rodman & Renshaw Conferences, LLCLily Khaykina, 1-212-356-0529Conference ManagerLK@rodm.com
$CONX - Corgenix Medical Provides Update on Ebola Test Kit NIH Grant
9:15 AM ET, 08/11/2014 - Business Wire
Corgenix and Viral Hemorrhagic Fever Consortium partners start work on Ebola rapid diagnostic test kit development, provide status update and project timeline
DENVER--(BUSINESS WIRE)--Aug. 11, 2014-- Ebola virus outbreaks tend to occur every few years and then go away rapidly. However, this year’s outbreak is the worst in recorded history, with the total number of deaths approaching 1,000. As reported previously, Corgenix Medical Corporation (OTCBB:CONX), a worldwide developer and marketer of diagnostic test kits, commenced work on a $2.9 millionNational Institutes of Health (NIH) grant in June.
In the past, Corgenix has served as a subcontractor to Tulane University for several NIH-funded grants and contracts related to development of diagnostics, vaccines and therapeutics for hemorrhagic fever viruses such as Lassa, Ebola and Marburg. Corgenix currently serves as the principal investigator for the new NIH-funded three-year contract to complete the development of recombinant diagnostic tests for Ebola.
The most recent grant was awarded to Corgenix and members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University. The NIH phase II, R44 grant was awarded to Corgenix and VHFC to develop rapid diagnostic tests (RDT) for Ebola, enabling rapid response to public health and bioterrorism threats posed by the deadly virus. Corgenix and the VHFC have previously developed and CE marked the ReLASV® rapid test for the Lassa fever virus.
Corgenix CEO Douglass Simpson said that as a reaction to the recent outbreak, the VHFC has shifted most of its efforts to the final phase of activity contemplated by the current NIH grant. Simpson also noted that, contrary to recent reports in the press, Corgenix has not finalized development of the Ebola products. “I want to strongly emphasize that this is a new three-year project, building off work commenced in 2010. We do not currently have an Ebola test nor will we likely have a final one in the near future,” said Simpson. “We understand the critical nature of this virus and are doing everything possible to accelerate efforts to develop reliable and rapid result diagnostic kits in order to be ready for the next outbreak.”
According to Robert Garry, Ph.D., Professor of Microbiology and Immunology at the Tulane University School of Medicine and Principal Investigator of the VHFC, “This is uncharted territory, and we’re all working with a heightened sense of urgency. Our goal is to be prepared for future outbreaks with rapid, accurate, point-of-care testing to diagnose or rule out both Ebola and Lassa, wherever it occurs, leading to quicker and more effective treatment, thus limiting the spread of the virus.”
The Ebola RDT has not yet been approved or cleared for clinical or diagnostic use by any worldwide regulatory authority.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
About the Viral Hemorrhagic Fever Consortium
The Viral Hemorrhagic Fever Consortium was established in 2010 as a result of several multi-year grants and contracts awarded to Tulane University by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to support Tulane's ongoing efforts to treat and prevent Lassa fever. The goal of the Consortium is to understand mechanisms related to the human immune response to Lassa virus infection. Specifically, by understanding what parts of the virus are recognized by the immune system, scientists can better understand mechanisms of antibody-mediated protection or pathogenesis in humans with Lassa fever. Consortium efforts have focused on the development of new recombinant proteins for Lassa virus diagnostic products, which have shown to be extremely effective in clinical settings in Africa. This progress is allowing a transition of efforts towards instituting better treatment of affected individuals and ultimately prevention of Lassa fever altogether. The Consortium is a collaboration between Tulane, Scripps Research Institute, Harvard University/Broad, University of Texas Medical Branch, Autoimmune Technologies LLC, Corgenix Medical Corporation, Kenema Government Hospital (Sierra Leone), the Irrua Specialist Teaching Hospital (Nigeria), Université de Lausanne (Switzerland), Zalgen Labs, LLC, and various other partners in West Africa. More information is available at www.vhfc.org.
Research detailed in this publication is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R44AI088843. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factorsthat would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
Source: Corgenix Medical Corporation
Company Contact:Corgenix Medical Corp.William Critchfield, Senior VP Operations and Finance and CFOPhone: 303-453-8903Email: wcritchfield@corgenix.comorMedia Contact:Armada Medical MarketingDan Snyders, Vice President and Public Relations SupervisorPhone: 303-623-1190 x230Email: dan@armadamedical.com
$CONX - Corgenix Medical Provides Update on Ebola Test Kit NIH Grant
9:15 AM ET, 08/11/2014 - Business Wire
Corgenix and Viral Hemorrhagic Fever Consortium partners start work on Ebola rapid diagnostic test kit development, provide status update and project timeline
DENVER--(BUSINESS WIRE)--Aug. 11, 2014-- Ebola virus outbreaks tend to occur every few years and then go away rapidly. However, this year’s outbreak is the worst in recorded history, with the total number of deaths approaching 1,000. As reported previously, Corgenix Medical Corporation (OTCBB:CONX), a worldwide developer and marketer of diagnostic test kits, commenced work on a $2.9 millionNational Institutes of Health (NIH) grant in June.
In the past, Corgenix has served as a subcontractor to Tulane University for several NIH-funded grants and contracts related to development of diagnostics, vaccines and therapeutics for hemorrhagic fever viruses such as Lassa, Ebola and Marburg. Corgenix currently serves as the principal investigator for the new NIH-funded three-year contract to complete the development of recombinant diagnostic tests for Ebola.
The most recent grant was awarded to Corgenix and members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University. The NIH phase II, R44 grant was awarded to Corgenix and VHFC to develop rapid diagnostic tests (RDT) for Ebola, enabling rapid response to public health and bioterrorism threats posed by the deadly virus. Corgenix and the VHFC have previously developed and CE marked the ReLASV® rapid test for the Lassa fever virus.
Corgenix CEO Douglass Simpson said that as a reaction to the recent outbreak, the VHFC has shifted most of its efforts to the final phase of activity contemplated by the current NIH grant. Simpson also noted that, contrary to recent reports in the press, Corgenix has not finalized development of the Ebola products. “I want to strongly emphasize that this is a new three-year project, building off work commenced in 2010. We do not currently have an Ebola test nor will we likely have a final one in the near future,” said Simpson. “We understand the critical nature of this virus and are doing everything possible to accelerate efforts to develop reliable and rapid result diagnostic kits in order to be ready for the next outbreak.”
According to Robert Garry, Ph.D., Professor of Microbiology and Immunology at the Tulane University School of Medicine and Principal Investigator of the VHFC, “This is uncharted territory, and we’re all working with a heightened sense of urgency. Our goal is to be prepared for future outbreaks with rapid, accurate, point-of-care testing to diagnose or rule out both Ebola and Lassa, wherever it occurs, leading to quicker and more effective treatment, thus limiting the spread of the virus.”
The Ebola RDT has not yet been approved or cleared for clinical or diagnostic use by any worldwide regulatory authority.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
About the Viral Hemorrhagic Fever Consortium
The Viral Hemorrhagic Fever Consortium was established in 2010 as a result of several multi-year grants and contracts awarded to Tulane University by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to support Tulane's ongoing efforts to treat and prevent Lassa fever. The goal of the Consortium is to understand mechanisms related to the human immune response to Lassa virus infection. Specifically, by understanding what parts of the virus are recognized by the immune system, scientists can better understand mechanisms of antibody-mediated protection or pathogenesis in humans with Lassa fever. Consortium efforts have focused on the development of new recombinant proteins for Lassa virus diagnostic products, which have shown to be extremely effective in clinical settings in Africa. This progress is allowing a transition of efforts towards instituting better treatment of affected individuals and ultimately prevention of Lassa fever altogether. The Consortium is a collaboration between Tulane, Scripps Research Institute, Harvard University/Broad, University of Texas Medical Branch, Autoimmune Technologies LLC, Corgenix Medical Corporation, Kenema Government Hospital (Sierra Leone), the Irrua Specialist Teaching Hospital (Nigeria), Université de Lausanne (Switzerland), Zalgen Labs, LLC, and various other partners in West Africa. More information is available at www.vhfc.org.
Research detailed in this publication is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R44AI088843. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factorsthat would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
Source: Corgenix Medical Corporation
Company Contact:Corgenix Medical Corp.William Critchfield, Senior VP Operations and Finance and CFOPhone: 303-453-8903Email: wcritchfield@corgenix.comorMedia Contact:Armada Medical MarketingDan Snyders, Vice President and Public Relations SupervisorPhone: 303-623-1190 x230Email: dan@armadamedical.com
$IMSC - Implant Sciences: Smart response by management:
http://www.prnewswire.com/news-releases/implant-sciences-responds-to-levi--korsinsky-llp-press-release-solicitation-270732121.html
$IMSC - Implant Sciences: Smart response by management:
http://www.prnewswire.com/news-releases/implant-sciences-responds-to-levi--korsinsky-llp-press-release-solicitation-270732121.html
Smart response by management.
Incorrect. CONX revenues exceed $10 Million. In addition the co is profitable.
Bravo. You can probably figure out who the law firm was fronting for.
To the Longs: Keep your eye on the prize.
Fishing expedition for the shorts.
$IMSC - Implant Sciences Reached a New 52 Week High at $1.32
Edit: $1.35 New High Today
Alert Triggered for Implant Sciences Corp.
IMSC rose 0.76% to a new 52 week high of $1.32. During the last 52 weeks, IMSC's price has ranged from $0.72 on February 14, 2014 to today's high of $1.32.
Additionally, over the last 12 months, IMSC has increased 10.92% while its peers in the Electronic Equipment & Instruments industry increased 13.78%.
Please note you will receive only one "New 52 Week High" alert per day for Implant Sciences Corp.
$IMSC - Implant Sciences Reached a New 52 Week High at $1.32
Edit: $1.35 New High Today
Alert Triggered for Implant Sciences Corp.
IMSC rose 0.76% to a new 52 week high of $1.32. During the last 52 weeks, IMSC's price has ranged from $0.72 on February 14, 2014 to today's high of $1.32.
Additionally, over the last 12 months, IMSC has increased 10.92% while its peers in the Electronic Equipment & Instruments industry increased 13.78%.
Please note you will receive only one "New 52 Week High" alert per day for Implant Sciences Corp.
$IMSC - Implant Sciences HOD 1.31 + .06 just off 52 WH of 1.32 on late buying surge.
$IMSC - Implant Sciences HOD 1.31 + .06 just off 52 WH of 1.32 on late buying surge.